by nms-sync | Jun 28, 2022 | News
Nerviano Medical Sciences (NMS Srl) a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, is pleased to announce the signing of the agreement with Università del Piemonte Orientale, faculty of...
by nms-sync | May 31, 2022 | News
BrYet is an American biotechnology company based in Houston TX founded for the purpose of developing and bringing to market drugs for prevention and treatment of multiple types of metastatic cancer, based on a disruptive approach developed by Prof. Mauro Ferrari:...
by nms-sync | May 5, 2022 | News
Nerviano, 5 May 2022
NMS Group SpA today announced that its CEO, Hugues Dolgos, has accepted the resignation of Angelo Colombo as CEO of Accelera Srl and NerPharMa Srl, effective 31 May 2022. Hugues Dolgos will act as interim CEO for both companies. A...
by nms-sync | Feb 7, 2022 | News
Nerviano, 7 February 2022
NMS Group, the center of excellence of oncology research and development in the heart of the Lombardy region is honored to receive the visit by Ms. Isabella Tovaglieri, Member of the European Parliament, Mr. Emanuele Monti, Chairman of...
by nms-sync | Jan 17, 2022 | News
Nerviano, 17 January 2022
The Shareholders’ Meeting of NMS Group S.p.A. (the “Company”) has appointed new Board of Directors for a three-year term. Tak-Wai (David) Wong has been named Chairman of the Board. Other newly appointed board members are...
by nms-sync | Sep 29, 2021 | News
NMS Group is proud to be named by Pharma Tech Outlook as Top drug discovery and development solution providers in Europe for 2021 and featured in the cover of this special issue.
The annual list showcases companies that are providing cutting-edge drug...
Recent Comments